Minerva Biotechnologies Inc., of Waltham, Mass., and ID Pharma Co. Ltd. (formerly Dnavec), of Ibaraki, Japan, said they signed an agreement granting Minerva worldwide rights to use and commercialize ID's non-integrating Sendai virus vectors together with Minerva's technology for generating induced pluripotent stem (iPS) cells.